ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BBIO BridgeBio Pharma Inc

30.86
0.00 (0.00%)
Last Updated: 14:57:52
Delayed by 15 minutes

Period:

Draw Mode:

Volume 644,401
Bid Price 30.84
Ask Price 30.86
News -
Day High 31.2175

Low
12.75

52 Week Range

High
44.32

Day Low 30.37
Company Name Stock Ticker Symbol Market Type
BridgeBio Pharma Inc BBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 30.86 14:57:52
Open Price Low Price High Price Close Price Prev Close
30.78 30.37 31.2175 30.86
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,495 644,401 $ 30.78 $ 19,834,446 - 12.75 - 44.32
Last Trade Time Type Quantity Stock Price Currency
14:57:52 69 $ 30.86 USD

BridgeBio Pharma (BBIO) Options Flow Summary

Overall Flow

Bearish

Net Premium

-63k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

BridgeBio Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.43B 175.83M - 9.3M -643.2M -3.66 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

BridgeBio Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BBIO Message Board. Create One! See More Posts on BBIO Message Board See More Message Board Posts

Historical BBIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week29.5431.2328.5129.791,509,0321.324.47%
1 Month36.0336.4126.8229.731,960,652-5.17-14.35%
3 Months38.0241.0426.8233.891,799,303-7.16-18.83%
6 Months26.2244.3223.6232.791,652,9644.6417.70%
1 Year14.3044.3212.7527.532,110,90516.56115.80%
3 Years60.2265.334.9821.042,023,789-29.36-48.75%
5 Years30.6173.504.9824.101,504,8050.250.82%

BridgeBio Pharma Description

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Your Recent History

Delayed Upgrade Clock